Perlmutter Cancer Center, New York University Langone Health, New York, New York.
Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne Germany.
J Thorac Oncol. 2020 Apr;15(4):520-540. doi: 10.1016/j.jtho.2020.01.016. Epub 2020 Feb 1.
The outcomes of patients with SCLC have not yet been substantially impacted by the revolution in precision oncology, primarily owing to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunotherapy are beginning to show promise in the clinic. Although, these results are encouraging, many patients do not respond to, or rapidly recur after, current regimens, necessitating alternative or complementary therapeutic strategies. In this review, we discuss ongoing investigations into the pathobiology of this recalcitrant cancer and the therapeutic vulnerabilities that are exposed by the disease state. Included within this discussion, is a snapshot of the current biomarker and clinical trial landscapes for SCLC. Finally, we identify key knowledge gaps that should be addressed to advance the field in pursuit of reduced SCLC mortality. This review largely summarizes work presented at the Third Biennial International Association for the Study of Lung Cancer SCLC Meeting.
小细胞肺癌患者的治疗结果尚未受到精准肿瘤学革命的实质性影响，主要是因为能够靶向治疗的驱动基因的遗传改变很少。然而，包括免疫疗法在内的全身治疗方法在临床上开始显示出希望。尽管这些结果令人鼓舞，但许多患者对当前的治疗方案没有反应，或者在治疗后迅速复发，这需要替代或补充治疗策略。在这篇综述中，我们讨论了对这种难治性癌症的病理生物学的研究进展，以及该疾病状态暴露的治疗弱点。讨论包括小细胞肺癌当前生物标志物和临床试验现状的概述。最后，我们确定了应该解决的关键知识空白，以推进该领域的研究，降低小细胞肺癌的死亡率。这篇综述主要总结了第三届国际肺癌研究协会小细胞肺癌会议上的报告内容。
